Quanterix

Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Its products and services include Simoa Assay Kits, HD-X analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, 2470 Arrayer, Simoa Accelerator Laboratory, Uman NF-Light, and Homebrew -Custom Assay Development. The company was founded by Nicholas J. Naclerio and David R. Walt in April 2007 and is headquartered in Billerica, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Quanterix reports strong Q4 revenue, eyes growth in neurology diagnostics

Quanterix's Q4 performance showcased revenue growth and margin improvement, underpinned by advancements in assay manufacturing and the launch of new tests. The company faces challenges in revenue management and cost control but has opportunities to drive growth through core products and competitive positioning in neurology diagnostics.

Quanterix reports robust Q1 earnings, eyes neuro research growth

Quanterix delivered strong Q1 results with revenue growth and margin improvements, while facing challenges in cash management and meeting revised guidance targets.
The company's focus on neuro research and clinical applications, along with its transformation plan, positions it well for future growth and market leadership.
Analyst inquiries highlighted areas for improvement and clarity, signaling the need for continued strategic communication and operational enhancements.

Quanterix reports robust Q2 earnings, eyes growth in diagnostics market

Quanterix's Q2 performance reflects strong revenue growth and improved profitability.
The company's focus on innovative diagnostics for Alzheimer's and neurological therapies positions it well for future growth.
Despite challenges in leadership transition and addressing specific patient needs, Quanterix remains optimistic about market adoption of blood biomarkers.

Quanterix reports strong Q3 revenue growth and advances in Alzheimer's diagnostics

Quanterix's Q3 performance reflects revenue growth, improved gross margins, and strategic collaborations in blood biomarker testing for Alzheimer's disease.
The company's strengths in expanding platform access, operational efficiency, and multimarker approaches present growth opportunities in diagnostics.
Challenges include meeting revenue growth expectations, maintaining high sensitivity levels in diagnostics, and balancing margin improvements with investments.
Opportunities exist in leveraging partnerships, developing innovative biomarker solutions, and capitalizing on the demand for comprehensive diagnostic tools in healthcare.

Quanterix reports record revenue in Q4 2023, eyes Alzheimer's diagnostics

Quanterix's Q4 2023 performance reflects strong revenue growth, improved margins, and strategic focus on innovation and market expansion.
While challenges in capital allocation and sustaining growth persist, the company's opportunities in menu expansion and Alzheimer's diagnostics are promising.
Overall, Quanterix's financial outlook for 2024 appears positive, with a clear roadmap for growth and continued market penetration.

Quanterix reports revenue growth and innovation drive amidst competition challenges

Quanterix's Q1 2024 performance reflects revenue growth, margin improvement, and innovation in disease detection assays, positioning the company for future success.
Strategic strengths include strong gross margins, successful product launches, and growth in Accelerator Lab services, driving revenue and market presence.
Challenges include competition assessment, margin maintenance, and regulatory milestones, while opportunities exist in innovation, revenue growth, and profitability focus.

Quanterix reports robust Q3 earnings, eyes growth in Alzheimer's diagnostics

Quanterix's strong revenue growth, focus on innovation, and strategic priorities position the company for continued success in the diagnostics market.
While facing challenges in maintaining gross margins and navigating regulatory landscapes, Quanterix has opportunities to drive growth through advanced diagnostics and market expansion.
By balancing customer mix, expanding menu offerings, and investing in new technologies, Quanterix is poised to capitalize on the growing demand for precision medicine and Alzheimer's disease testing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer, Masoud Toloue, and Chief Financial Officer, Vandana Sriram, will attend the Scotiabank Healthcare 1x1 Day on June 20, 2024. To learn more about Quanterix, visit www.quanterix.com/company. To learn more about Quanterix's Simoa® technology, visit www.quanterix.com/simoa-technology. About Quanterix.

Quanterix to Participate at the Scotiabank Healthcare 1x1 Day

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will speak at the Goldman Sachs 45th Annual Global Healthcare Conference. Toloue will speak alongside Chief Financial Officer Vandana Sriram in a fireside chat presentation on Wednesday, June 12, 2024, at 2:40 p.m. EST. The session will be made available to attendees and the general.

Quanterix to Present at 45th Annual Goldman Sachs Global Healthcare Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will speak in a fireside chat at the 2024 Leerink Partners Healthcare Crossroads Conference. Quanterix's presentation is scheduled for Wednesday, May 29, 2024, at 11:40 a.m. ET. The fireside chat will be made available to attendees and to the public via webcast. Webcast Information T.

Quanterix to Present at Leerink Partners Healthcare Crossroads Conference 2024

The consensus price target hints at a 67.7% upside potential for Quanterix (QTRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Quanterix (QTRX) Could Rally 67.66%: Here's is How to Trade

Quanterix Corporation (NASDAQ:QTRX ) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET Company Participants Francis Pruell - Investor Relations Masoud Toloue - President and Chief Executive Officer Vandana Sriram - Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners Matt Sykes - Goldman Sachs Kyle Mikson - Canaccord Genuity Sung Ji Nam - Scotiabank Dan Brennan - TD Cowen Operator Good day and thank you for standing by. Welcome to the Quanterix Corporation Q1 2024 Earnings Call Conference Call.

Quanterix Corporation (QTRX) Q1 2024 Earnings Call Transcript

Quanterix Corporation (QTRX) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.16 per share a year ago.

Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the first quarter ended March 31, 2024. “Building on the foundation our team developed last year, Quanterix is entering a new innovation and product delivery phase,” said Masoud Toloue, Chief Executive Officer of Quanterix. “We've announced the first of several new assays that could re-define the way Tau.

Quanterix Releases Financial Results for the First Quarter of 2024

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Wednesday, May 8, 2024 at 8:30 a.m. E.T., to discuss its first quarter 2024 financial results. Quanterix will issue a press release regarding the first quarter 2024 earnings prior to the conference call on Tuesday, May 7, 2024 after the market closes. The press release will be posted on.

Quanterix To Report First Quarter 2024 Financial Results

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced a specific partnership path for laboratories interested in offering Tau based research and diagnostic testing services. Quanterix has secured over thirty U.S. patents protecting our innovative ultra-sensitive research products and high-definition diagnostics, and we continue to secure additional patent protection, both.

Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer's Disease Testing Infrastructure

Quanterix's (QTRX) blood-based biomarker test offers a non-invasive alternative, potentially revolutionizing how AD is diagnosed and managed.

Quanterix (QTRX) AD Offering Gets FDA's Breakthrough Device Tag

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, announced today that its Simoa® phospho-Tau 217 (p-Tau 217) blood test has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) as an aid in diagnostic evaluation of Alzheimer's Disease (AD). The FDA's Breakthrough Device designation is granted to products that have the potential to offer more eff.

Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer's Disease

Quanterix Corporation (QTRX) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.50 per share a year ago.

Quanterix Corporation (QTRX) Reports Q4 Loss, Tops Revenue Estimates

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the fourth quarter and twelve months ended December 31, 2023. “The fourth quarter marked the successful completion of our corporate transformation. We now have a strong, scalable foundation for growth and innovation,” said Masoud Toloue, President and Chief Executive Officer of Quanterix. “Our research b.

Quanterix Releases Operating Results for Fourth Quarter and Full Year 2023

Quanterix's (QTRX) blood-based biomarker testing offers a superior alternative, aligning with the recommendations of the NIA-AA criteria for AD diagnosis.

Quanterix (QTRX) Expands in Alzheimer's Testing With Alliances

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX) today announced that it has rescheduled the release of its financial results for the fourth quarter and year ended December 31, 2023 and the associated conference call in order to more closely align the release of such results with the filing of its Annual Report on Form 10-K for the year ended December 31, 2023, the deadline for which is February 29, 2024. The investor call will now be held on Thursday, February 29, 2024.

Quanterix Reschedules Q4 and Full Year 2023 Earnings Conference Call; Reaffirms 2023 Guidance

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced its first collaborations with health systems in pursuit of their shared goal to improve and simplify Alzheimer's disease (AD) diagnosis. These relationships further the company's goal to build the global infrastructure necessary for AD testing by expanding clinical access to Quanterix's leading blood biomarker assays. C.

Quanterix Announces First Collaborations with Five Health Networks to Aid the Diagnosis and Clinical Management of Individuals with Alzheimer's Disease

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will present at Cowen's 44th Annual Health Care Conference. Quanterix's session will take place on Monday, March 4, 2024, at 12:50 p.m. EST and will be made available to attendees and, via webcast, the general public. In addition to the session, Quanterix will also host one-on-one me.

Quanterix to Present at Cowen's 44th Annual Health Care Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced it will host a conference call on Tuesday, February 27, 2024, to discuss its fourth quarter earnings and full year 2023 financial results. The call will begin at 8:30 AM Eastern Time. It will be hosted by Masoud Toloue, the Company's President and Chief Executive Officer, and Vandana Sriram, the Company's Chief Financial Offi.

Quanterix Fourth Quarter Earnings and Full Year 2023 Financial Results Conference Call

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the 42nd Annual J.P. Morgan Healthcare Conference. Quanterix's session will take place on Wednesday, January 10, 2024, at 5:15 p.m., PST. Webcast Information The live webcast presentation can be accessed here and from the Investors section of the company.

Quanterix to Present at 42nd Annual J.P. Morgan Healthcare Conference

Does Quanterix Corporation (QTRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Quanterix Corporation (QTRX) is a Great Momentum Stock to Buy

The mean of analysts' price targets for Quanterix Corporation (QTRX) points to a 33.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Quanterix Corporation (QTRX) Have the Potential to Rally 33.74% as Wall Street Analysts Expect?

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will speak in a fireside chat at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 16, 2023 at 3:00 PM ET. To access the live webcast, please register here. A replay will be available following the conference on Qua.

Quanterix To Participate at The Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

The mean of analysts' price targets for Quanterix Corporation (QTRX) points to a 54.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 54.88% Upside in Quanterix Corporation (QTRX): Can the Stock Really Move This High?

Quanterix Corporation (NASDAQ:QTRX ) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Ed Joyce - VP, IR Masoud Toloue - President and CEO Vandana Sriram - CFO Conference Call Participants Kyle Mikson - Canaccord Genuity Jake Allen - Goldman Sachs Dan Brennan - Cowen Puneet Souda - Leerink Partners Operator Good day and thank you for standing by. Welcome to the Quanterix Corporation Q3 2023 Earnings Call.

Quanterix Corporation (QTRX) Q3 2023 Earnings Call Transcript

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation today announced financial results for the three months ended September 30, 2023.

News for Quanterix Stock (QTRX)